Summit Securities Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-1,500
Closed -$34K – 870
2023
Q3
$34K Buy
+1,500
New +$33.6K ﹤0.01% 322

Other funds holding RYTM

Summit Securities Group's RYTM Position: Q3 2026 in Review

Summit Securities Group sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2026, closing a stake of 543 shares — an estimated $60.3K sold.

Summit Securities Group first reported a position in RYTM in Q2 2026 and held it in 1 quarter. The position peaked at $60.3K in Q2 2026. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Summit Securities Group reported no remaining Rhythm Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Summit Securities Group sold 543 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $60.3K.
  • Summit Securities Group first reported a position in Rhythm Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Summit Securities Group's Rhythm Pharmaceuticals position peaked at $60.3K in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.